MEK and PI3K inhibition in solid tumors: rationale and evidence to date

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The PI3K-AKT-mTOR and Ras-Raf-MEK-ERK pathways are frequently altered in solid tumors.
• Single-agent inhibitors targeting these pathways have shown limited efficacy in most cancers.
• Preclinical data suggest combination therapy may be effective.

Purpose of the Study:

• To review preclinical evidence for dual PI3K and MEK targeting in cancer.
• To analyze early-phase clinical trial results of this combination therapy.
• To propose future research directions for PI3K/MEK dual targeting.

Main Methods:

• Literature review of preclinical studies on PI3K and MEK dual targeting.
• Analysis of data from early-phase clinical trials investigating this combination.
• Synthesis of findings to inform future therapeutic strategies.

Main Results:

• Preclinical studies indicate synergistic antitumor activity with dual PI3K and MEK inhibition.
• Early clinical trials are exploring the safety and efficacy of this approach.
• Specific solid malignancies may benefit from concurrent pathway inhibition.

Conclusions:

• Dual targeting of PI3K-AKT-mTOR and Ras-Raf-MEK-ERK pathways represents a promising therapeutic strategy.
• Further clinical investigation is warranted to optimize combination regimens.
• This approach holds potential for improving treatment outcomes in solid malignancies.